Show notes
In this episode, we explore Lilly TuneLab as a major signal of where AI drug discovery may be heading: toward powerful platform ecosystems that combine proprietary pharmaceutical data, advanced predictive models, federated learning, and large-scale compute. On the positive side, platforms like TuneLab could help biotech companies derisk drug assets earlier, improve safety and pharmacokinetic predictions, reduce wasted experiments, and give smaller teams access to capabilities once reserved for Big Pharma. At the same time, this new model raises important questions about scientific…
Website: podcasters.spotify.com

